RT Journal Article
T1 Impact of Pseudomonas aeruginosa Infection on Patients with Chronic Inflammatory Airway Diseases.
A1 Garcia-Clemente, Marta
A1 de la Rosa, David
A1 Máiz, Luis
A1 Girón, Rosa
A1 Blanco, Marina
A1 Olveira, Casilda
A1 Canton, Rafael
A1 Martinez-García, Miguel Angel
K1 COPD
K1 Pseudomonas aeruginosa
K1 asthma
K1 bronchiectasis
K1 chronic bronchial infection
K1 cystic fibrosis
AB Pseudomonas aeruginosa (P. aeruginosa) is a ubiquitous and opportunistic microorganism and is considered one of the most significant pathogens that produce chronic colonization and infection of the lower respiratory tract, especially in people with chronic inflammatory airway diseases such as asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and bronchiectasis. From a microbiological viewpoint, the presence and persistence of P. aeruginosa over time are characterized by adaptation within the host that precludes any rapid, devastating injury to the host. Moreover, this microorganism usually develops antibiotic resistance, which is accelerated in chronic infections especially in those situations where the frequent use of antimicrobials facilitates the selection of "hypermutator P. aeruginosa strain". This phenomenon has been observed in people with bronchiectasis, CF, and the "exacerbator" COPD phenotype. From a clinical point of view, a chronic bronchial infection of P. aeruginosa has been related to more severity and poor prognosis in people with CF, bronchiectasis, and probably in COPD, but little is known on the effect of this microorganism infection in people with asthma. The relationship between the impact and treatment of P. aeruginosa infection in people with airway diseases emerges as an important future challenge and it is the most important objective of this review.
SN 2077-0383
YR 2020
FD 2020-11-24
LK https://hdl.handle.net/10668/26167
UL https://hdl.handle.net/10668/26167
LA en
DS RISalud
RD Apr 17, 2025